Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Approved for marketing × Breast Neoplasms × eribulin × Clear all

Status

Completed 50 Recruiting 12 Unknown 11 Terminated 10 Active not recruiting 8 Withdrawn 5 Not yet recruiting 5 Suspended 1 Approved for marketing 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1

Interventions

abemaciclib 2 zenocutuzumab 1 selpercatinib 1 eribulin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01240421 2015-05-22

An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory

Eisai Inc.

Approved for marketing

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡